Terms ending in 2038
Every in-force patent on Intervet Inc.'s record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,065,324 | Combination Vaccine for Swine In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,311,614 | Vaccines Containing Swine Pathogens for Associated Non-Mixed Use In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,135,285 | Swine Vaccine In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 10,372,967 | Automated Parasite Analysis System In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,741,731 | Automated Parasite Analysis System In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,077,181 | A Vaccine Comprising a PCV2 ORF2 Protein of Genotype 2B In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,167,021 | A Vaccine for Protection Against Streptococcus Suis In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,696,944 | Vaccine for Protection Against Streptococcus Suis In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 12,295,999 | Vaccine for Protection Against Streptococcus Suis In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,229,698 | Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Multiple Heterologous Antigens In force · High confidence | Intervet Inc. | In force | High confidence | |
| 17 more term ends in 2038 · Pro | |||||
10 of 27 patents shown. Soonest term end first, then patent number.
Pro members see all 27.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.